GSK expects Advair price crunch, ViiV IPO decision

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) expects continued price pressure on respiratory drug Advair salmeterol/fluticasone propionate this year and said it is likely to reveal a decision on a

Read the full 275 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE